

Date: November 14, 2018

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd.
Vibgyor Towers, 4th Floor, Plot No. C-62,
G-Block, Opp. Trident, Bandra-Kurla Complex,
Bandra (E), Mumbai-400 098

Sub: Outcome of Board Meeting held on Today, November 14, 2018

Dear Respected Sir / Madam,

With reference to above captioned subject, please note that the Board of Directors of Jagadishwar Pharmaceutical Works Limited at its meeting held on November 14, 2018, amongst other matters, consider to consider, IND AS Unaudited Financial Results of the Company for the quarter ended on September 30, 2018 along with Limited Review Report thereon in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

We request you to kindly take above on record.

Thanking You,

Yours Faithfully,

For Jagadishwar Pharmaceutical Works Limited


Swapan Sarkar
Managing Director
DIN : 05149442

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd. Office : 205, Haribol Roy Market, A.T.Road

2nd Floor, Near Saraf Building, Guwahati - 781 001

Email: jpwld@yahoo.com, Website: jagadishwarpharma.com, Tel.: +91 9163513467

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

(Rs. In Lacs)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2018	30-06-2018	30-09-2017	30-09-2018	30-09-2017	31-03-2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income From Operations	-	-	23.00	-	104.00	110.00
II	Other Income	0.43	0.43	16.36	0.88	30.66	96.43
III	Total Income from operations (I + II)	0.43	0.43	39.36	0.88	134.66	206.43
IV	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	65.71	451.75
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	24.50	-	77.60	(302.20)
	(d) Employee benefits expense	0.98	1.48	1.64	2.49	3.29	7.19
	(e) Depreciation and amortisation expense	-	-	-	-	-	1.39
	(f) Finance Cost	-	-	-	-	-	-
	(g) Other expenses	1.07	2.93	0.92	3.98	3.38	6.07
	Total Expenses	2.05	4.41	27.06	6.47	149.98	164.20
V	Profit (Loss) before exceptional Items and extraordinary items and tax (III-IV)	(1.62)	(3.98)	12.30	(5.59)	(15.32)	42.23
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit from ordinary activities before finance costs and Exceptional Items (V-VI)	(1.62)	(3.98)	12.30	(5.59)	(15.32)	42.23
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Net Profit/(Loss) before tax (VII-VIII)	(1.62)	(3.98)	12.30	(5.59)	(15.32)	42.23
X	Tax Expense :						
	(1) Current Tax	-	-	-	-	2.22	9.35
	(2) Deferred Tax	-	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	2.22	9.35
XI	Net profit/(Loss) for the period from continuing operations (IX-X)	(1.62)	(3.98)	12.30	(5.59)	(17.54)	32.88
XII	Profit/(Loss) for the period from discontinuing operations	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) for the period from discontinuing operations (after tax)	-	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(1.62)	(3.98)	12.30	(5.59)	(17.54)	32.88
XVI	Other Comprehensive Income	-	-	-	-	-	-
XVII	Total Comprehensive Income	-	-	-	-	-	-
XVIII	Paid up equity share capital (Face Value of Rs. 10/- per Share)	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02
XIX	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	10.36
XX	Earnings Per Share (EPS)						
	(a) Basic	(0.00)	(0.00)	0.00	(0.00)	(0.01)	0.01
	(b) Diluted	-	-	-	-	-	-

Notes:

1 The above results are in compliance with Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. The results for the previous periods have been restated as per Ind AS. The standalone financial results of the Company for the quarter and half year ended 30th September, 2018 have been reviewed by the Audit Committee at their meeting held on 14th November, 2018 and have been approved by the Board of Directors at its meeting held on 14th November, 2018.

2 Reconciliation of Net Profit & Equity as previously reported under India GAAP (IGAAP) and Ind-AS for the quarters/periods are presented as under:

Particulars	Net Profit Reconciliation			Equity Reconciliation
	Quarter ended	Period ended	Year ended	As at
	30-09-2017	30-09-2017	31-03-2018	31-03-2018
Net Profit/Equity as per IGAAP	-	-	-	-
Appreciation/ (Diminution) in value of Investments	-	-	-	-
Reclassification of Net Actuarial (Gain) / Loss on employee defined benefit obligation to other comprehensive income	-	-	-	-
Net Profit/Equity as per Ind-AS	-	-	-	-
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income/Equity as per Ind-AS	-	-	-	-

3 The standalone financial results of the Company for the quarter and half year ended 30th September, 2018 have been unaudited by the Statutory Auditors.

4 The Statutory Auditors have carried out a "Limited Review" of the above financial results for the quarter/half ended 30th September, 2018.

5 Previous period/Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited

Place : Guwahati
Date : 14.11.2018



Director
(CIN: L24232AS1987PLC002803)

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd. Office : 205, Haribol Roy Market, A.T.Road

2nd Floor, Near Saraf Building, Guwahati - 781 001


Standalone Statement of Assets and Liabilities

(Rs. In Lacs)

Sr No	Particulars	Current year ended September 2018	Previous year ended September 2017
	Assets		
1	Non-current assets		
	Property, plant and equipment	-	1.39
	Capital work-in-Progress	-	-
	Investment property	-	-
	Goodwill	-	-
	Other Intangible assets	-	-
	Biological assets other than bearer plants	-	-
	Investments accounted for using equity method	-	-
	Non-current financial assets	-	1.39
	Non-current investments	1,302.84	1,352.84
	Trade receivables, non-current	6.14	10.91
	Loans, non-current financial assets	-	-
	Total non-current financial assets	1,308.98	1,363.75
	Deferred tax assets (net)	-	-
	Other non-current assets	283.27	583.12
	Total non-current assets	1,592.25	1,948.26
2	Current assets		
	Inventories	1,425.24	1,045.44
	Current financial assets		
	Current investments	-	-
	Trade receivables, current	0.02	-
	Cash and cash equivalents	0.53	25.29
	Bank balance other than cash and cash equivalents	0.43	0.97
	Loans, current	-	-
	Other current financial assets	-	-
	Total current financial assets	0.98	26.26
	Current tax assets (net)	-	-
	Other current assets	-	-
	Total current assets	1,426.22	1,071.70
3	Non-current assets classified as held for sale		
	Regulatory deferral account debit balance and related	-	-
	Deferred tax assets	-	-
	Total assets	3,018.47	3,019.96
	Equity and liabilities		
1	Equity		
	Equity attributable to owners of parent		
	Equity share capital	2,970.02	2,970.02
	Other equity	48.28	4.33
	Total equity attributable to owners of parents	3,018.30	2,974.35
	Non controlling assets	-	-
	Total equity	3,018.30	2,974.35
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	-	-
	Trade payables, non-current	-	45.61
	Other non-current liabilities	0.17	-
	Total Non-current financial liabilities	0.17	45.61
	Provision, non-current	-	-
	Deferred tax liabilities (net)	-	-
	Deferred government grants, Non-current	-	-
	Other non-current liabilities	-	-
	Total non-current liabilities	-	-
	Current liabilities		
	Current financial liabilities		
	Borrowings current	-	-
	Trade payables, current	-	-
	Other current financial liabilities	-	-
	Short-term provisions	-	-
	Total current financial liabilities	-	-
	Other current liabilities	-	-
	Provisions, current	-	-
	Current tax liabilities (Net)	-	-
	Deferred government grants, current	-	-
	Total current liabilities	0.17	45.61
3	Liabilities directly associated with assets in disposal group classified as held for sale		
	Regulatory deferral account credit balance and related deferred tax liability	-	-
	Total liabilities	0.17	45.61
	Total equity and liabilities	3,018.47	3,019.96

For Jagadishwar Pharmaceutical Works Limited

Place: Kolkata
Dated: 14.11.2018



Directors
(08/19442)

Ref :

Date :

LIMITED REVIEW REPORT

To

The Board of Directors,

Jagadishwar Pharmaceutical Works Limited

We have reviewed the unaudited financial results of **Jagadishwar Pharmaceutical Works Limited** (“the Company”), for the quarter ended September 30, 2018 together with the notes thereon (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), which has been initialed by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company’s opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim financial information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to the following matters:

- a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2018, and accordingly, the Statement has been prepared by the Company’s Management in compliance with Ind AS.
- b) We were neither engaged to review, nor have we reviewed the comparative figures including reconciliation to the Total Comprehensive Income for the quarter ended on September 30, 2018. As set out in note 5 to the Statement, these figures have been furnished by the Management.

Place : Kolkata

Date : 14th November, 2018

For Shantimay Majumder & Co.
Chartered Accountants
Firm Regd. No.-317116E
57, Ramesh Mitra Road, 1st Floor, Kol-25

S. Majumder Saantimoy Majumder
(Proprietor)

S. Majumder
Proprietor M. No. 053264
Firm Regn. No.: 317116E